论文部分内容阅读
本文报告用COP、COMP方案治疗非何杰金氏淋巴瘤(NHL).其中COP组46例,CR16例(34.8%);COMP组22例,CR12例(54.5%).二组无显著差异(P>0.05),但COP组有6例PR,经改用COMP方案获CR,说明二方案无交叉耐药性,COMP方案可作为对COP方案耐药时的替代方案.COP及COMP方案的主要毒副反应均以消化道症状为主,但绝大多数病人可耐受全程化疗.上述二方案较为安全且疗效尚佳,可作为初治及复治的NHL的首选及替换方案使用.
This article reports the use of COP and COMP regimens for the treatment of non-Hodgkin’s lymphoma (NHL), including 46 COP patients and 16 CR patients (34.8%), 22 patients with COMP and 12 (54.5%) CR patients, with no significant difference between the two groups P> 0.05), but there were 6 cases of PR in COP group and CR of COMP group, which indicated that there was no cross-resistance in the two regimens and COMP regimen could be used as an alternative to COP regimen resistance.COP and COMP regimen main Toxicity and side effects are mainly gastrointestinal symptoms, but the vast majority of patients can tolerate the whole course of chemotherapy.The above two programs are relatively safe and effective, and can be used as the first choice and retreatment of NHL preferred and alternative use.